A patient has died after receiving the high dose of Neurogene’s Rett syndro | A patient has died after receiving the high ...

Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...

AstraZeneca has ended work on an opioid use disorder (OUD) drug after the orexin 1 receptor antagonist demonstrated a ...

Novartis had one eye on the struggles its peers have encountered in the muscular dystrophy space when it decided to acquire ...

Last November, Pyxis revealed it would continue to focus on PYX-201 as its lead asset, while pausing other early-stage ...

Halozyme Therapeutics has withdrawn its $2.1 billion offer to buy Evotec after the German company “has been unwilling to ...

Volker Herrmann, M.D., has also stepped away from the helm, with Sonata chairman David Khougazian taking the wheel as acting ...

In another sign of biopharma's waning interest in the traditional ex vivo gene therapy approach, CSL Behring is shutti | CSL ...

They need to find a bigger venue,” an attendee mutters as they pull their coat tight and brave the British rain to find one ...

Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral ...

Novartis has slimmed down its clinical-stage programs by nearly 40% in recent years as the Big Pharma “took to heart” data ...

Genmab's Anthony Pagano sat down with Fierce Biotech at the Jefferies conference in London to talk M&A, asset ownership and ...